Drug
Mp0533 Monotherapy
Mp0533 Monotherapy: highest development phase Phase 1, developed by Molecular Partners. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Molecular Partners
Trials
| Drug | Phase | Indication |
|---|---|---|
| MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 NCT05673057 | Phase 1 | Leukemia |
Latest
No recent events.
Follow Mp0533 Monotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.